Abstract:【Abstract】 Objective To observe the expression of serum carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCCA), progastrinreleasing peptide (ProGRP) and cytokeratin 19 fragment (CYFRA21-1) in pulmonary squamous cell carcinoma (SQC) and analyze their relationship with the prognosis. Methods 80 patients with SQC (SQC group), 80 patients with benign benign pulmonary lesions (benign lesion group), and 80 healthy patients (control group) were selected as the subjects. Serum CEA, SCCA, ProGRP and CYFRA 21-1 levels were compared among the three groups, and their relationships with pathological characteristics and prognosis of SQC were analyzed. Results The serum levels of CEA, SCCA, ProGRP and CYFRA21-1 1 in SQC group were significantly higher than those in benign lesion group and control group (P＜0.05). There was no significant difference between benign lesion group and control group (P＞0.05). The high expression rates of CEA, SCCA, ProGRP and CYFRA21-1 in patients with TNM stage Ⅲ～Ⅳ, lymph node metastasis and infiltration degree T3～T4 were significantly higher than those in TNM stage Ⅰ～Ⅱ, no lymph node metastasis and infiltration degree T1～T2 (P＜0.05). Multivariate logistic analysis showed that serum CEA, SCCA, ProGRP and CYFRA21-1 were independent risk factors for SQC (P＜0.05). Kaplan Meier survival analysis showed that the overall survival rate of patients with high expression of CEA, SCCA, ProGRP and CYFRA21-1 was significantly lower than that of patients with low expression (P＜0.05). Conclusion The expression levels of serum CEA, SCCA, ProGRP and CYFRA21-1 show an increasing trend in patients with SQC, and they are related to tumor stage, lymph node metastasis and infiltration degree. They can be used to evaluate the prognosis of patients.
